CD80 transfected human hepatocellular carcinoma cells activate cytotoxic T lymphocytes to target HCC cells with shared tumor antigens

Oncology Reports

Volumn 12, Issue 2, 2004, Pages 435-442

  Chan, Ray Chun Fai ^a   Xie, Yong ^a  

^a HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

Author keywords

Co stimulatory molecule CD80; Cytotoxic T lymphocytes; Electroporation; Hepatocellular carcinoma; Shared tumor antigen

Indexed keywords

B7 ANTIGEN; COMPLEMENTARY DNA; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; TUMOR ANTIGEN;

ARTICLE; BIOSYNTHESIS; CELL SEPARATION; CELL STRAIN K 562; CHEMISTRY; CYTOTOXIC T LYMPHOCYTE; ELECTROPORATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETIC TRANSFECTION; HISTOCOMPATIBILITY TEST; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; MOLECULAR CLONING; T LYMPHOCYTE; TIME; TUMOR CELL LINE;

ANTIGENS, CD80; ANTIGENS, NEOPLASM; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL SEPARATION; CLONING, MOLECULAR; DNA, COMPLEMENTARY; ELECTROPORATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HISTOCOMPATIBILITY TESTING; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; INTERFERON TYPE II; K562 CELLS; LIVER NEOPLASMS; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; TIME FACTORS; TRANSFECTION;

EID: 16544370589     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.12.2.435     Document Type: Article

References (34)

1. Stern MC, Umbach DM, Yu MC, London SJ, Zhang ZQ and Taylor JA: Hepatitis B, aflatoxin Bl, and p53 condon 249 mutation in hepatocellular carcinomas from Guangxi, People's republic of China, and a meta-analysis of existing studies. Cancer Epidemiol Biomarkers Prev 10: 617-625, 2001. (Pubitemid 32703195)
2. Bosch X, Ribes J and Borras J: Epidemiology of primary liver cancer. Semin Liver Dis 19: 271-285, 1999. (Pubitemid 29488770)
3. Munoz N and Bosch X: Epidemiology of hepatocellular carcinoma. In: Neoplasms of the Liver. K Okuda and KG Ishak (eds). Tokyo, Springer, pp3-19, 1987.
4. Chan RCF, Xie H, Zhao GP and Xie Y: Dendritomas formed by fusion of mature dendritic cells with allogenic human hepatocellular carcinoma cells activate autologous cytotoxic T lymphocytes. Immunol Lett 83: 101-109, 2002. (Pubitemid 34626943)
5. Ichida T, Higuchi K, Arakawa K, Ohta H, Sugiyama K, Miyagiwa M and Nohzawa A: Treatment of hepatocellular carcinoma utilizing lymphokine-activated killer cells and inter-leukin-2. Cancer Chemother Pharmacol 2: 45-48, 1990.
6. Uchino J, Une Y, Kawata A, Wakisaka Y and Hosokawa M: Postoperative chemoimmunotherapy for the treatment of liver cancer. Semin Surg Oncol 9: 332-336, 1993. (Pubitemid 23216374)
7. Suto T, Fukuda S, Moriya N, Watanabe Y, Sasaki D, Yoshida Y and Sakata Y: Clinical study of biological response modifiers as maintenance therapy for hepatocellular carcinoma. Cancer Chemother Pharmacol 33: S145-S148, 1994. (Pubitemid 24147986)
8. Himoto T, Watanabe S, Nishioka M, Tanaka S and Saito M: Combination immunotherapy with OK432, recombinant granulocyte-colony stimulating factor and recombinant interleukin-2 for human hepatocellular carcinoma. Cancer Immunol Immunother 42: 127-131, 1996. (Pubitemid 26109529)
9. Boon T, Cerrotini JC, van den Eynde B, van den Bruggen B and van Pel A: Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12: 337-365, 1994. (Pubitemid 24140418)
10. Hellström KE, Hellström I, Hellman S and Rosenberg SA: The Biologic Therapy of Cancer. J.B. Lippincot Co., Philadelphia, pp35-42, 1991.
11. Bretscher P and Cohn M: A theory of self-nonself discrimination. Science 169: 1042, 1970.
12. Gimmi CD, Freeman GJ, Gribben JG, Gray G and Nadler LM: Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc Natl Acad Sci USA 90: 6586-6590, 1993. (Pubitemid 23207258)
13. Cavallo F, Martin-Fontecha A, Bellone M, Heltai S, Gatti E, Tornaghi P, Freschi M, Forni G, Dellabona P and Casorati G: Co-expression of B7-1 and ICAM-1 on tumor is required for rejection and the establishment of a memory response. Eur J Immunol 25: 1154-1162, 1995.
14. Huang J, Cai MY and Wei DP: HLA class I expression in primary hepatocellular carcinoma. World J Gastroenterol 8: 654-657, 2002. (Pubitemid 34918658)
15. Talmage DW, Woolnough JA, Hemmingsen H, Lopez L and Laferty KJ: Activation of cytotoxic T cells by nonstimulating tumor cells and spleen cell factor(s). Proc Natl Acad Sci USA 74: 4610-4614, 1977. (Pubitemid 8225175)
16. Chen L, Linsley PS and Hellström KE: Costimulation of T cells for tumor immunity. Immunol Today 14: 483-486, 1993. (Pubitemid 23300998)
17. Shi M, Wang FS and Wu ZZ: Synergetic anticancer effect of combined quercetin and recombinant adenoviral vector expressing human wild-type p53, GM-CSF and B7-1 genes on hepato-cellular carcinoma cells in vitro. World J Gastroenterol 9: 73-78, 2003. (Pubitemid 36131282)
18. Schwartz RH: Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 71: 1065-1079, 1992.
19. Liu Y and Linsley PS: Costimulation of T cell growth. Curr Opin Immunol 4: 265-270, 1992.
20. Linsley PS, Brady W, Grosmaire L, Aruffo A, Damle NK and Ledbetter JA: Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin-2 mRNA accumulation. J Exp Med 173: 721-730, 1991.
21. Linsley PS, Brady W, Urnes M, Grosmaire L, Damle NK and Ledbetter JA: CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 174: 561-569, 1991.
22. +T cells specific for transporter associated with antigen processing deficient cells. Proc Natl Acad Sci USA 94: 11496-11501, 1997.
23. Sadanaga N, Nagashima H, Mashino K, Tahara K, Yamaguchi H, Ohta M, Fujie T, Tanaka F, Inoue H, Takesako K, Akiyoshi T and Mori M: Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin Cancer Res 7: 2277-2284, 2001. (Pubitemid 32751625)
24. Renner C, Trumper L and Pfreundschuh M: Tumor vaccines: a new immunotherapeutic approach in oncology. Ann Hematol 79:651-659, 2000. (Pubitemid 32016384)
25. Tahara K, Mori M, Sadanaga N, Sakamoto Y, Kitano S and Makuuchi M: Expression of the MAGE gene family in human hepatocellular carcinoma. Cancer 85: 1234-1240, 1999. (Pubitemid 29125075)
26. Robbins PF, El-Gamil M, Li YF, Zeng G, Dudley M and Rosenberg SA: Multiple HLA Class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma. J Immunol 169: 6036-6047, 2002. (Pubitemid 35291712)
27. Ostrand-Rosenberg S, Roby CA and Clements VK: Abrogation of tumorigenicity by MHC class II antigen expression requires the cytoplasmic domain of the class II molecules. J Immunol 147: 2419-2422, 1991.
28. Bodmer WF, Browning MJ, Krausa P, Rowan A, Bicknell DC and Bodmer JG: Tumor escape from immune response by variation in HLA expression and other mechanisms. Ann NY Acad Sci 690: 42-49, 1993. (Pubitemid 23278692)
29. Fenton RG, Turcovski-Corrales SM and Taub DD: Induction of melanoma antigen-specific cytotoxic T lymphocytes in vitro by stimulation with B7-expressing human melanoma cell line. J Immunother 21: 95-108, 1998. (Pubitemid 28141713)
30. Yang S, Darrow TL and Seigler HF: Generation of primary tumor-specific cytotoxic T lymphocytes from autologous and human lymphocyte antigen class I-matched allogenic peripheral blood lymphocytes by B7 gene-modiied melanoma cells. Cancer Res 57: 1561-1568, 1997. (Pubitemid 27175575)
31. Holmes LM, Li J, Sticca RP, Wagner TE and Wei YZ: A rapid novel strategy to induce tumor cell-specific cytotoxic T lymphocyte responses using instant dendritomas. J Immunotherapy 24: 122-129, 2001. (Pubitemid 32183058)
32. Ward S, Casey D, Labarthe MC, Whelan M, Dalgleish A, Pandha H and Todryk S: Immunotherapeutic potential of whole tumour cells. Cancer Immunol Immunother 51: 351-357, 2002. (Pubitemid 35002039)
33. Van der Merwe PA and Davis SJ: Molecular interactions mediating T cell antigen recognition. Annu Rev Immunol 21: 659-684, 2003.
34. Chen L, McGowan P, Ashe S, Johnston J, Li Y, Hellström I and Hellström KE: Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med 179: 523, 1994.